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Autism spectrum disorder (ASD)
A B S T R A C T
Autism spectrum disorders (ASD) are a group of heterogeneous neurodevelopmental conditions characterized by
impaired social interaction, and repetitive stereotyped behaviours. Interestingly, functional and inﬂammatory
gastrointestinal diseases are often reported as a comorbidity in ASDs, indicating gut-brain axis as a novel
emerging approach. Recently, a central role for peroxisome-proliferator activated receptor (PPAR)-α has been
addressed in neurological functions, associated with the behaviour. Among endogenous lipids, palmitoyletha-
nolamide (PEA), a PPAR-α agonist, has been extensively studied for its anti-inﬂammatory eﬀects both at central
and peripheral level.
Based on this background, the aim of this study was to investigate the pharmacological eﬀects of PEA on
autistic-like behaviour of BTBR T+tf/J mice and to shed light on the contributing mechanisms.
Our results showed that PEA reverted the altered behavioural phenotype of BTBR mice, and this eﬀect was
contingent to PPAR-α activation. Moreover, PEA was able to restore hippocampal BDNF signalling pathway, and
improve mitochondrial dysfunction, both pathological aspects, known to be consistently associated with ASDs.
Furthermore, PEA reduced the overall inﬂammatory state of BTBR mice, reducing the expression of pro-in-
ﬂammatory cytokines at hippocampal, serum, and colonic level. The analysis of gut permeability and the ex-
pression of colonic tight junctions showed a reduction of leaky gut in PEA-treated BTBR mice. This ﬁnding
together with PEA eﬀect on gut microbiota composition suggests an involvement of microbiota-gut-brain axis.
In conclusion, our results demonstrated a therapeutic potential of PEA in limiting ASD symptoms, through its
pleiotropic mechanism of action, supporting neuroprotection, anti-inﬂammatory eﬀects, and the modulation of
gut-brain axis.
1. Introduction
Autism spectrum disorders (ASD) are a range of complex neurode-
velopmental conditions characterized by impaired social interaction,
isolated areas of interest, and repetitive stereotyped behaviours
(Maresca and de Magistris, 2015). The aetiology of ASD is likely mul-
tifactorial and based on genetic, epigenetic and environmental risk
factors, although the precise molecular and cellular links remain ill-
deﬁned (Waye and Cheng, 2018). Previously, we have demonstrated
that genetic inactivation of peroxisome-proliferator activated receptor
(PPAR)-α, particularly abundant in the CNS (Moreno et al., 2004), leads
to a behavioural and cognitive phenotype reminiscent of that of pre-
clinical models of ASD, including the mouse model BTBR T+tf/J
(BTBR), which displays an improved repetitive behaviour, when au-
tistic mice were treated with a synthetic PPAR-α agonist (D'Agostino
et al., 2015). These results not only indicated a central role for this
receptor in neurological functions associated with the behaviour, but
more interestingly highlighted PPAR-α as a potential pharmacological
target to lessen ASD symptoms. Notably, in sodium valproate (VPA)-
induced model of ASD it has been shown a reduction in PPAR-α ex-
pression in frontal cortex accompanied by an increase of several fatty
acid ethanolamides at hippocampal levels following exposure to the
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sociability test, including palmitoylethanolamide (PEA), and oley-
lethanolamide (OEA), identiﬁed as PPAR-α endogenous agonists (Kerr
et al., 2013). Moreover, it has been demonstrated that the administra-
tion of PEA in combination with luteolin, was eﬀective in reducing
social and behavioural defects shown by sodium VPA-induced autistic
mice (Bertolino et al., 2017).
ASDs have been associated with several comorbidities, including
immune dysregulation and gastrointestinal ailments (Ashwood et al.,
2011; Buie, 2013; Coury et al., 2012; Li et al., 2009; Morgan et al.,
2010; Vargas et al., 2005). Indeed, in recent years a focus on the role of
the bidirectional communication between the GI tract and the CNS,
namely gut-brain axis, has been addressed in the pathogenesis of sev-
eral brain disorders (Mayer et al., 2014; Wang and Kasper, 2014), in-
cluding ASDs, whose therapeutic strategies are overlooked (Cristiano
et al., 2018). The aetiology of GI abnormalities in ASDs is unclear,
though the association between GI dysfunction and ASD-associated
behaviours suggests that overlapping developmental defects in the
brain and the intestine could be responsible for the observed pheno-
types. Actually, GI alterations in terms of inﬂammation and leaky gut
can contribute to the pathogenesis or lead to the progression of brain
disorders. We have recently shown that marked intestinal dysbiosis,
and damage were shown in BTBR mice, together with an impairment of
gut integrity and an increase of inﬂammatory cytokines expression in
colonic tissue (Coretti et al., 2017), indicating an increased gut per-
meability and translocation of pro-inﬂammatory factors across the in-
testinal epithelium into the bloodstream.
Gut inﬂammation and impairment of gut integrity can be associated
with microbial dysbiosis. In BTBR mice alteration of gut microbiota
composition has been recently describes: in particular, in BTBR mice
gut microbiota alterations have been found to be associate with im-
paired behaviour, immune system dysregulation and GI alteration
(Coretti et al., 2017; Klein et al., 2016). BTBR mice showed a phenotype
that mirror many ASD pathological aspects found in children patients,
including alterations in both innate and adaptive arms of the immune
system (Onore et al., 2013).
Here, we have studied the eﬀect of PEA treatment on autistic-like
phenotype of BTBR mice, exploring the underpinning molecular me-
chanisms involved at hippocampal level. In particular, we investigated
the contingency of PPAR-α activation/function in PEA beneﬁcial ef-
fects, the involvement of brain derived neurotrophic factor (BDNF)
signalling pathway and mitochondrial function and eﬃciency.
Furthermore, the modulating eﬀect of PEA on gut permeability and
inﬂammation was assessed, in order to investigate the involvement of
gut-brain axis, evaluating systemic cytokines and gut microbiota com-
position.
2. Materials and methods
2.1. Animals
Male C57Bl/6J (B6), B6.129S4-SvJae-Pparatm1Gonz PPAR-alpha
null (KO) and BTBR T+tf/J (BTBR) (3–4months old) mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME, USA) and co-
lonies maintained in our animal facility genotyped according to sup-
plier webpage (http://jaxmice.jax.org), using the RedExtract kit
(Sigma–Aldrich, Italy).
All animals were housed in groups in a room maintained at 22 °C, on
a 12 h:12 h light:dark cycle, with ad libitum access to water and stan-
dard laboratory chow diet. To minimalized litter eﬀects, we used mice
from at least 5 diﬀerent litters in each experiment. All experimental
procedures were carried out in compliance with the international and
national law and policies (EU Directive 2010/63/EU for animal ex-
periments, ARRIVE guidelines and the Basel declaration including the
3R concept) and approved by Italian Ministry of Health.
2.2. Drugs and treatment
Ultra-micronized PEA (PEA-um®; Epitech Group, Italy) and
GW6471 (N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(triﬂuoromethyl)
phenyl)prop-1-enyl) amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-
yl)ethoxy)phenyl)propyl) propanamide), a PPAR-α antagonist (GW;
Tocris, Bristol, UK) were dissolved in PEG400, Tween 80 and sterile
saline (Sigma-Aldrich, Milan, Italy) to obtain a ﬁnal concentration of
PEG400 and Tween 80 of 20 and 10% v/v, respectively and injected at
a volume of 10ml/kg body weight.
BTBR, KO and control B6 mice were daily intraperitoneal-injected
(i.p.) for 10 days with Vehicle, PEA (10 or 30mg/kg), and/or GW
(1mg/kg). When BTBR mice were co-treated with PEA and GW, the
antagonist was injected 30min before PEA administration. Testing
began at ages 3–4months, on day 9th, one hour after the last injection.
In details, behavioural tasks described below were conducted in the
same mice from 5 diﬀerent litters, in a battery on two separate days
(9th-10th) according to Paylor et al. (2006), with suﬃcient intervals
between tests and in a sequence that begins with the least stressful
quick observational tests followed by the more stressful complex tasks,
except for the valuation of locomotor activity and anxiety behaviour
(elevated plus maze and open ﬁled test) that were conducted on a se-
parate cohort of mice. All experiments and data analyses were per-
formed by operators blinded to genotype, when possible, and treat-
ment.
2.3. Marble burying assay
20 marbles were arranged in a 5x4 grid in a Plexiglas cage ﬁlled
with 5 cm of clean bedding. Each mouse was individually placed into
this cage and allow to freely explore for 30 min. At the end of the
session, the mouse was gently removed and the number of buried
marbles (< 2/3 visible above bedding) were counted by the tester.
2.4. Self-Grooming test
Mice were placed in an empty Plexiglas cage (30 x 40 cm) and left
undisturbed freely to explore the arena. Following 10min of habitua-
tion, the self-grooming activity was manual scored by a trained ob-
server for other 20min. Grooming behaviour included head washing,
body grooming, genital/tail grooming and paw and leg licking.
2.5. Three-chambered social test
Social interaction was examined using the three-chambered appa-
ratus as previously described (Crawley, 2004). Brieﬂy, this test consists
of 3 phases; the ﬁrst one is a 5-minute habituation to the empty arena.
In the following 10min session of social preference, the experimental
mouse is exposed to an inanimate object in one side of the chamber and
a stimulus mouse in the other chamber. Then, the third ﬁnal 10-minute
phase of social novelty consists to evaluate mouse preference between
the known mouse and a novel stimulus mouse placed in the previously
inanimate object chamber. Time spent in sniﬃng the object or mouse
and time spent in each chamber were automatically detected by a vi-
deocamera coupled with a video-tracking software (Any-maze,
Stoelting).
2.6. In vivo intestinal permeability assay
In vivo intestinal permeability assay was performed for a subset of
mice using ﬂuorescein isothiocyanate-labeled dextran (FITC-dextran)
method, as previously described (Cani et al., 2009). Brieﬂy, food and
water were withdrawn for 6 h and mice (n= 5, each group) were ad-
ministrated by gavage with FITC labeled dextran 4000 (Sigma-Aldrich,
Milan, Italy), as permeability tracer (60mg/100 g body weight). After
24 h blood of all animals was collected by intracardiac puncture and
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centrifuged (3000 rpm for 15min at RT). Then plasma FITC-dextran
concentration was determined (excitation, 485 nm; emission, 535 nm;
HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley, MA, USA), using
a standard curve generated by serial dilution of the tracer.
2.7. Western blotting
Hippocampus was homogenized in lysis buﬀer (50mM Tris–HCl, pH
7.4; 1 mM EDTA; 100mM NaCl; 20mM NaF; 3mM Na3VO4; 1mM
PMSF with 1% (v/v) Nonidet P-40; and protease inhibitor cocktail).
Lysates were centrifuged at 20,000g for 15min at 4 °C. Protein con-
centrations were estimated using bovine serum albumin as a standard
in a Bradford reagent assay. Proteins were separated on SDS-PAGE,
transferred to nitrocellulose membranes, and incubated with the fol-
lowing primary antibodies: PPAR-α (cat no P0369, Sigma Aldrich),
1: 500; Bdnf (cat no sc-546, Santa Cruz), 1: 200; pCREB (cat no 9196,
Cell Signaling Technologies (CST), MA, USA), 1:1000; CREB (cat no
4820, CST) 1: 2000; β-actin (Sigma Aldrich), 1:1000. The signals were
visualized with the ECL system (Pierce) by Image Quant (GE Healtcare,
Milan, Italy). The protein bands were densitometrically analyzed with
the Quantity One software (Bio-Rad Laboratories).
2.8. Real-time PCR analysis
Total RNA was extracted from hippocampus and colon using Trizol
(Ambion). Two micrograms of total RNA were used in ﬁrst-strand cDNA
synthesis (Promega, Madison, WI) according the manufacturer in-
structions. PCRs were performed with a Bio-Rad CFX96 Connect Real-
time PCR System instrument and software (Bio-Rad Laboratories). The
PCR conditions were 15min at 95 °C followed by 40 cycles of two-step
PCR denaturation at 94 °C for 15 s, annealing extension at 55 °C for 30 s
and extension at 72 °C for 30 s. Each sample contained 500 ng cDNA in
2X QuantiTech SYBRGreen PCR Master Mix and primers Ppara, Bdnf,
Ntrk2, Tnfa, Il1b, Il6, Ocln and Tjp1 purchased from Qiagen (Hilden,
Germany). The relative amount of each studied mRNA was normalized
to GAPDH as housekeeping gene, and the data were analyzed according
to the 2–ΔΔCT method.
2.9. Serum parameters
Blood was collected and serum obtained by centrifugation. Serum
Tnf-α, Il-1β and Il-6 were measured using commercially available ELISA
kits (Thermo Fisher Scientiﬁc, Rockford, IL), following the manu-
facturer’s instructions.
2.10. Mitochondrial parameters
Hippocampal mitochondrial isolation and oxygen consumption
were performed as previously reported (Lama et al., 2017). Oxygen
consumption was polarographically measured using a Clark-type elec-
trode in the presence of substrates and ADP (state 3) or with substrates
alone (state 4), and the respiratory control ratio was calculated. The
degree of coupling was determined by applying equation by Cairns
et al. (1998): = −degree of coupling Jo Jo1 ( ) /( )sh unc where (Jo)sh re-
presents the oxygen consumption rate in the presence of oligomycin
that inhibits ATP synthase, and (Jo)unc is the uncoupled rate of oxygen
consumption induced by carbonyl cyanide p-tri-
ﬂuoromethoxyphenylhydrazone (FCCP), which dissipates the transmi-
tochondrial proton gradient. (Jo)sh and (Jo)unc were measured as above
using succinate (10mmol/l) rotenone (3.75 µmol/l) in the presence of
oligomycin (2 µg/ml) or FCCP (1 µmol/L), respectively. The speciﬁc
activity of superoxide dismutase (SOD) was measured spectro-
photometrically, as previously reported (Flohe and Otting, 1984).
2.11. Oxidative stress assay
The levels of ROS were determined by the procedure of Montoliu
et al. (1994). Brieﬂy, fresh hippocampal homogenate was diluted in
100mM potassium phosphate buﬀer (pH 7.4) and incubated with a
ﬁnal concentration of 5 μM dichloroﬂuorescein diacetate (Sigma–Al-
drich) in dimethyl sulfoxide for 15min at 37 °C. The dye-loaded sam-
ples were centrifuged and the pellet suspended in 100mM potassium
phosphate buﬀer and incubated for 60min at 37 °C. The ﬂuorescence
measurements were performed with a HTS-7000 Plus-plate-reader
spectroﬂuorometer (Perkin Elmer, Wellesley, Massachusetts, USA) at
488 nm for excitation and 525 nm for emission wavelengths. Reactive
oxygen species (ROS) stress were quantiﬁed from the dichloroﬂuoresce
in standard curve in dimethyl sulfoxide (0–1mM).
2.12. 16S metagenomic sequencing and data analysis
Fecal samples were collected from a subset of six mice randomly
selected from each group and quickly stored at −80 °C. Fecal micro-
biota was studied by performing V3-V4 16S rDNA amplicon sequencing
in order to obtain the operational taxonomic units (OTUs) deﬁning the
bacterial communities. Sequencing samples from frozen fecal pellets
were prepared, sequenced and subsequently processed as previously
described (Coretti et al., 2017). To avoid sample size biases in sub-
sequent analyses, samples were normalized to 10,595 sequences/
sample using a sequence rarefaction procedure. To assess sampling
depth coverage and species heterogeneity in each sample, alpha di-
versity metrics were employed on rareﬁed OTU tables using Good’s
coverage, Observed species and Shannon’s diversity index. A two-
sample permutation t-test, using 999 Monte Carlo permutations to
compute p-value, was performed to compare the alpha diversities be-
tween sample groups. OTUs diversity among sample communities (beta
diversity) was assessed by applying unweighted and weighted UniFrac
distances. Statistical signiﬁcance of beta diversities was assessed on
phylogenetic distances matrixes using ANOSIM method with 999 per-
mutations. Statistical diﬀerences in OTUs frequencies among groups
across diﬀerent taxonomic levels were assessed through one-way
ANOVA followed by Tukey multiple comparison post-hoc tests.
2.13. Statistical analysis
Data are presented as mean ± SEM. All the experiments were
analyzed using analysis of variance (ANOVA) for multiple comparisons
followed by Bonferroni’s post hoc test, using GraphPad Prism (GraphPad
software, San Diego, CA, USA). Statistical signiﬁcance was set at
p < 0.05 in all the statistical analyses.
3. Results
3.1. PEA reduces repetitive behaviour and increased sociability in BTBR
mice
The eﬀect of PEA on ASD-like behaviour was assessed by marble
burying, self-grooming, and 3-chambered social test. To examine the
repetitive/perseverative phenotype, mice of all groups were scored for
the number of marbles they bury from the top of the bedding and for
the time spent in home cage self-grooming. We observed that Vehicle
treated BTBR mice buried a greater number of marbles (Fig. 1A;
p < 0.0001) and displayed higher self-grooming scores (Fig. 1B;
p < 0.0001) compared with control Vehicle treated B6. PEA (10mg/
kg) induced a slight improvement in the repetitive behaviour, whereas
Bonferroni’s post hoc analysis indicated that at the highest dose
(30mg/kg) PEA signiﬁcantly decreased stereotyped behaviours in both
marble buried assay (Fig. 1A; F(3,36)= 23.78, p < 0.0001) and self-
grooming scores (Fig. 1B; F(3,36)= 18.40, p < 0.05).
To assess PPAR-α involvement in PEA eﬀect, BTBR mice were
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treated with the PPAR-α antagonist GW6471 before PEA administra-
tion. Bonferroni’s post hoc analysis revealed that the highest dose of
PEA failed in exerting its eﬀect on both repetitive behaviours (Fig. 1C; F
(4,45)= 19.51, p < 0.05. Fig. 1D; F(4,45)= 22.01, p < 0.01). The
antagonist alone had no eﬀect on BTBR mice in both behavioural
paradigms. Consistently, PEA treatment did not modify the autistic-like
traits showed by PPAR-α null mice (D'Agostino et al., 2015) in both
behavioural tests (Fig. 1E; F(2,26)= 10.42, p < 0.001. Fig. 1F; F
(2,24)= 12.39, p < 0.001), indicating the obligatory involvement of
PPAR-α.
In addition, we investigated the possible eﬀect of PEA on social
preference, using the three-chambered social test, evaluating the time
spent in the chamber with the object or with a mouse and the time spent
in sniﬃng the object or the mouse. Vehicle treated BTBR mice failed to
display signiﬁcant sociability both on time in the zone (Fig. 2A;
p < 0.01) and on time in social sniﬃng (Fig. 2B; p < 0.01) during the
second phase of the automated three-chambered social approach task
compared with Vehicle treated B6. PEA treatment improved sociability
of BTBR mice: at the dose of 10mg/kg, mice spent equal time in the
zone and in sniﬃng the novel mouse and the novel object, while, at
30 mg/kg, they signiﬁcantly spent more time in the mouse chamber and
in sniﬃng the mouse compared to the object (Fig. 2A; F(5,54)= 11.43,
p < 0.001; 2B; F(5,54)= 9.280, p < 0.001).
Then, PPAR-α involvement was assess in social behaviour of BTBR
mice. Results showed that PEA failed to improve sociability both in
time in the zone and in sniﬃng time of BTBR mice, when pre-treated
with GW (Fig. 2C; F(9,90)= 14.20p < 0.0001; Fig. 2D; F
(9,90)= 8.701p < 0.001). The antagonist alone had no eﬀect on BTBR
mice. PEA treated PPAR-α null mice showed equal time spent in the
mouse zone and in sniﬃng time with the mouse and the object (Fig. 2E;
F(5,52)= 2.780, p=0.1019). Vehicle treated PPAR-α null mice
showed a not signiﬁcant preference for the object side (Fig. 2F F
(5,54)= 4.088, t= 1.436).
During the last phase of the test, we analysed the time spent in area
and the time spent in sniﬃng familiar or new mouse (Supplementary
Fig. S1). All BTBR and B6 groups spent more time in the chamber with
the novel mouse than the familiar mouse, as well as in sniﬃng time,
indicating no behavioural impairment in this phase of the test in Ve-
hicle- or treated BTBR mice. Instead, Vehicle- or PEA-treated PPAR-α
null mice showed a signiﬁcant preference for the familiar mouse, con-
sistently with D'Agostino et al. (2015).
A single PEA administration (30mg/kg i.p.) in BTBR mice was also
tested, revealing 1 h after no eﬀect on all behavioural tests
(Supplementary Fig. S2) and then no early fast eﬀect of PEA adminis-
tration. Moreover, all behavioural skills were not aﬀected by PEA in B6,
indicating that this drug had no behavioural eﬀects per se in control
mice (Supplementary Fig. S3).
In order to exclude the induction of anxiety and/or locomotor def-
icits by drugs, we tested all mice in open ﬁeld and elevated plus maze
test, revealing no diﬀerence due to treatments, but only an overall
diﬀerence between strains (Supplementary Fig. S4).
3.2. PEA induces PPAR-α expression and BDNF/TrkB system at
hippocampal level
To strengthen PPAR-α role in autism, we subsequently evaluated
PPAR-α expression in the hippocampus. BTBR mice displayed a sig-
niﬁcant reduction in PPAR-α mRNA (p < 0.01) and protein
(p < 0.001) expression, that were signiﬁcantly reconstituted by PEA
treatment (30mg/kg) at both mRNA (p < 0.05) and protein
(p < 0.01) level (Fig. 3A; F(2,25)= 5.754. Fig. 3B; F(2,5)= 12.84).
Since impairment of BDNF/tropomyosin-related kinase B (TrkB)
pathway can contribute to behavioural deﬁcits related to autism, this
pathway was also investigated. Indeed, Bonferroni’s post doc analysis
showed signiﬁcant lower hippocampal level of BDNF and a not sig-
niﬁcant decreasing trend of TrkB in both mRNA (p < 0.05 and NS) and
protein expression (p < 0.05 and NS) in BTBR mice compared with B6
control mice (Fig. 3C; F(2,23)= 4,300. Fig. 3D; F(2,12)= 22.84.
Fig. 3E; F(2,18)= 15.114. Fig. 3F; F(2,9)= 11,78). PEA treatment
(30mg/kg) restored both BDNF (Fig. 3C; mRNA level p < 0.05.
Fig. 1. Eﬀect of PEA on repetitive stereotyped autist-like behaviour of BTBR mice and involvement of PPAR-α. (A-B) Number of buried marble and self-grooming
time of control B6 and BTBR mice following i.p. daily administration of Vehicle, PEA (10–30mg/kg) for 10 days (n= 10 each group). (C-D) number of buried marble
and self-grooming time of control B6 and BTBR mice following daily GW 6471 (GW, 1mg/kg i.p.) treatment alone or 1 hr before PEA (30mg/kg) for 10 days (n=10
each group). (E-F) Number of buried marble and self-grooming time of WT (n= 9) and PPAR-α null mice (KO) daily i.p. treated with Vehicle (n= 10) or PEA 30mg/
kg (n=10) for 10 days. All data are presented as means ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Fig. 2. Eﬀect of PEA on social behaviour of BTBR mice and involvement of PPAR-α. (A) Time in the zone (B) and sniﬃng time during the second social preference
phase of 3-chambered social test of control B6 and BTBR mice following i.p. daily administration of Vehicle, PEA (10–30mg/kg) for 10 days (n=10 each group). (C)
Time in the zone (D) and sniﬃng time during the sociability phase of 3-chambered social test of control B6 and BTBR mice following daily GW 6471 (GW, 1mg/kg
i.p.) treatment alone or 1 hr before PEA (30mg/kg) for 10 days (n= 10 each group). (E) Time in the zone (F) and sniﬃng time during the sociability phase of 3-
chambered social test of WT (n=9) and PPAR-α null mice (KO) daily i.p. treated with Vehicle (n= 10) or PEA 30mg/kg (n= 10) for 10 days. All data are presented
as means ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Fig. 3. PEA eﬀect on hippocampal gene transcription and expression. RT-PCR and western blot detection of PPAR-α (A-B), Bdnf (C-D) and TrkB mRNA and protein
(E-F) expression in the hippocampus from B6 and BTBR mice treated with Vehicle or PEA 30mg/kg (n=7–11 per group). RT-PCR of CREB (G) and western blot
detection of p-CREB and CREB (H) protein expression in the hippocampus from B6 and BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for
10 days (n= 6–8 per group). Representative western blot from a 2–3 animals each group following the above treatments are shown. Signals from each animal
quantiﬁed and peptide expression shown as a ratio of housekeeping gene β-Actin (Actin) and with total CREB. Results are expressed as mean ± s.e.m. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.001.
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Fig. 3D; protein level p < 0.0001) and TrkB expression (Fig. 3E; mRNA
level p < 0.05. Fig. 3F; protein level p < 0.01) in BTBR mice.
Therefore, activation of cAMP response element-binding protein
(CREB) downstream this pathway was investigated. Results showed
CREB mRNA level did not signiﬁcant changed by PEA treatment
(30mg/kg) in BTBR mice (Fig. 3G; F(2,20)=1,558), while, at protein
level, the signiﬁcant reduced phosphorylated state of CREB in BTBR
mice (p < 0.01) was restored by PEA treatment (p < 0.001) (Fig. 3H;
F(2,12)= 19.85).
3.3. PEA treatment improves hippocampal mitochondrial function and
reduces oxidative stress
Mitochondrial state 3 respiration using succinate as substrate was
decreased in BTBR mice compared with B6. Repeated treatments of PEA
restored mitochondrial respiration (Fig. 4A left side; F(2,13)= 30.22,
p < 0.001), whereas no variation was observed in mitochondrial state
4 respiration (Fig. 3A right side). No variation was found in oligomycin
state 4 respiration, while a signiﬁcant decrease was found in maximal
FCCP-stimulated respiration in PEA treated mice compared BTBR mice
(Fig. 4B). As a consequence, hippocampal mitochondrial energetic ef-
ﬁciency, assessed as degree of coupling, was signiﬁcantly lower in PEA
treated mice compared to BTBR mice (Fig. 4C F(2,33)= 3.700,
p < 0.01).
ROS production was signiﬁcantly increased in hippocampus from
BTBR mice (p < 0.01) and blunted by PEA treatment (Fig. 4D; F
(2,30)= 18.00, p < 0.001), similarly, BTBR mice showed a signiﬁcant
lower SOD activity (p < 0.001), which was restored by PEA (Fig. 4E; F
(2,8)= 25.50, p < 0.01).
3.4. PEA reduces systemic and tissue cytokines
Brain inﬂammation has been associated with the pathogenesis and
progression of ASD: in particular, pro-inﬂammatory cytokines correlate
with impaired sociability and aberrant behaviour linked to ASD in both
humans and mice (Heo et al., 2011; Theoharides et al., 2016). BTBR
mice showed a signiﬁcant increased level of TNFα (p < 0.01), IL-1β
(p < 0.01), and IL-6 (p < 0.01) in the hippocampus compared to B6
mice and signiﬁcant reductions of all cytokines TNFα (p < 0.01), IL-1β
(p < 0.05), and IL-6 (NS) were found in BTBR PEA mice compared to
BTBR group (Fig. 5A; F(2,18)= 11.84. Fig. 5B; F(2,14)= 9.711.
Fig. 5C; F(2,18)=9.096). In parallel, inﬂammatory cytokines were
elevated also in colon (p < 0.001, p < 0.001, p < 0.01 showed in
Fig. 5D F(2,17)= 72.61. Fig. 5E F(2,16)= 11.03. Fig. 5F; F
(2,15)= 12.21) and serum (all p < 0.001. Fig. 5G; F(2,15)= 43.61.
Fig. 5H; F(2,15)= 57.35. Fig. 5I; F(2,15)= 18.74) in BTBR mice
compared to B6 control mice. Bonferroni’s post doc analysis showed
that all cytokine, TNFα (p < 0.001), IL-1β (p < 0.05), and IL-6
(p < 0.01) at colonic level, TNFα (p < 0.001), IL-1β (p < 0.001), and
IL-6 (p < 0.01) as well as at serum level, were downregulated by PEA
treatment (Fig. 5D-I). These results revealed both peripheral and central
eﬀects of PEA in autistic mice, opening a new scenario on the me-
chanism of action of PEA.
3.5. PEA eﬀects on gut permeability and microbiota
BTBR mice are characterized by a compromised epithelial barrier
integrity: a signiﬁcant increase in gut permeability was shown in vivo in
BTBR mice evaluating the plasmatic levels of FITC-labelled dextran at
24 h (Fig. 6A; F(2,16)= 9.311, p < 0.01). PEA improved epithelial
barrier integrity (p < 0.05) of BTBR mice, increasing the transcription
of Tjp1 and Ocln mRNA transcripts (all p < 0.001) in colonic tissues
found signiﬁcantly reduced in BTBR mice compared to B6 control mice
(all p < 0.001; Fig. 6B; F(2,20)= 37.03. Fig. 6C; F(2,26)= 11.32).
Faecal microbiota composition was analysed by next-generation
sequencing method to evaluate the eﬀect of PEA administration on gut
Fig. 4. Eﬀect of PEA on mitochondrial and oxidative stress. (A) Mitochondrial respiration in the presence of succinate as substrate, (B) oxygen consumption in the
presence of oligomycin (left side), or uncoupled by FCCP (right side) and (C) degree of coupling values calculated from oxygen consumption in the presence of
oligomycin and uncoupled by FCCP in the hippocampus from B6 and BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n= 12
per group). (D) ROS production in the hippocampus from B6 and BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n=12 per
group). (E) SOD activity in the hippocampus from B6 and BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n= 5) All data are
presented as means ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001.
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Fig. 5. PEA modulation of central and peripheral inﬂammatory cytokines. Changes in Tnf-α, IL-1β, and IL-6 mRNA levels in hippocampus (A-C), and colon (D-F), and
cytokine analysis in serum (G-I) of B6 or BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n=6 per group). Results are showed
as mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 6. PEA eﬀect on intestinal permeability and faecal microbiota composition. (A) in vivo permeability detected by plasmatic levels of FITC-labelled dextran from
B6 or BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n=6 per group). (B-C) changes in mRNA expression of Tjp1 and Ocln in
colon tissue from B6 or BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n=6 per group). (D) Phylum level composition of
fecal microbiota from B6 and BTBR mice following daily i.p. administration of Vehicle or PEA 30mg/kg for 10 days (n= 6 per group). (E) Bacterial genera belonging
to Bacteroidetes and Firmicutes phyla found to be signiﬁcantly diﬀerent among groups (n= 6 per group). Results are showed as mean ± s.e.m. *p < 0.05;
**p < 0.01; ***p < 0.001 ****p < 0.0001.
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microbial communities of BTBR mice with respect to similar ages of
cases of untreated BTBR and B6 control mice. Alpha diversity analyses
did not show signiﬁcant alteration in bacterial species richness and
diversity within groups. On the contrary, measuring phylogenetic dis-
tances by beta diversity analyses, we found signiﬁcant diﬀerences in
microbial species assortment (unweighted beta diversity) among groups
(see Table S1, supplemental materials and data). Interestingly, R sta-
tistic ANOSIM, computed on phylogenetic distances among samples,
revealed that upon PEA treatment the overall microbial community of
BTBR mice was restructured and resulted signiﬁcantly diﬀerent from
that of untreated BTBR mice (Supplementary Table S1; BTBR vs BTBR-
PEA, R=0.0522; p < 0.01). PEA treatment strongly impacted on le-
vels of deﬁnite identiﬁed phyla. Among the 9 phyla detected, Bacter-
oidetes and Firmicutes were the most abundant and primarily aﬀected
by PEA treatment (Fig. 6D; F(16,135)= 4.049); Firmicutes/Bacter-
oidetes ratio was considerably higher in BTBR mice treated with PEA
due to signiﬁcant increase in Firmicutes and decrease in Bacteroidetes
(Fig. 5D; both p < 0.0001). At genus level, the increase of Firmicutes/
Bacteroidetes ratio upon PEA administration was mainly a consequence
of diminution of Bacteroides (p < 0.0001), U. g. of Rikenellaceae
(p < 0.01), U.g. of S24-7 (p < 0.0001) (phylum Bacteroidetes) and
increase of U.g. of Clostridiales (p < 0.0001) (phylum Firmicutes)
(Fig. 6E; F(162,1230)= 5.216). Thus, PEA treatment establishes a new
microbiota proﬁle, marking diﬀerences with microbiota composition
found in untreated BTBR mice and recovering similarities for some
aspects with microbial assortment of B6 control mice.
4. Discussion
In this study, we highlight the beneﬁcial and dose-dependent ac-
tivity of PEA on repetitive and stereotypic impairment, and social be-
haviour in BTBR autism mouse model, and shed light on the con-
tributing central and peripheral mechanisms, that may be involved in
this eﬀect.
Here, we have demonstrated that the positive eﬀect exerted by PEA
is contingent to PPAR-α activation, since receptor blockade by its an-
tagonist blunted the beneﬁcial behavioural eﬀect evoked by PEA in
BTBR mice. According to behavioural results, we found signiﬁcant
lower PPAR-α mRNA and protein expression in the hippocampus of
BTBR compared to B6 mice that was increased after PEA treatment of
BTBR mice. Moreover, this acylethanolamide failed in inducing its ef-
fect in ameliorating stereotyped behaviours in PPAR-α KO mice, which
exhibit a similar phenotypic-like autism behaviour in these tasks, dif-
ferently from social interaction that was not signiﬁcantly altered.
In BTBR mice, the higher dose of PEA signiﬁcantly improved re-
petitive behaviour in two behavioural tests and sociability in the three-
chambered assay. We excluded possible drug-induced confounding
hyper- or hypo- activity during behavioural assays by open ﬁeld and
elevated plus maze tests in all strains. Moreover, a single PEA admin-
istration had no eﬀect on all behavioural tests, indicating no early rapid
eﬀect of PEA administration, whereas pharmacological eﬀect appears
only after repeated administrations, most likely due to the consolida-
tion of PEA-induced mechanisms for a delayed eﬀect.
Only recently, limited literature shows the possible therapeutic
potential of PEA in ASDs. Speciﬁcally, Bertolino et al. (2017) found that
PEA combined with Luteolin ameliorates social and non-social im-
pairment in VPA-induced ASD in mice and reported a reduction of
behavioural alterations of an autistic child. Indeed, previously
Antonucci et al. (2015) had already published the ameliorating eﬀect of
PEA treatment in two teen-age boys, displayed as an improvement in
cognitive and behavioural skills. Very recently, PEA has been proposed
as an adjunctive therapy in autistic children receiving risperidone
(Khalaj et al., 2018), since the co-treatment was more eﬀective than
risperidone plus placebo, on irritability and hyperactivity symptoms,
suggesting once again the potential of PEA in counteracting the core
symptoms of autism.
Autism is a multifactorial disorder, where, many genes converge,
through multiple molecular mechanisms, onto common processes in-
volved in the development and function of neural circuits, whose al-
teration leads and sustains the core symptoms of ASDs (Geschwind,
2008). Evidence based on environmental factors, such as infection, gut
microbiome alteration, and immunological features are also growing,
suggesting the involvement of many scenarios worth investigating.
Obviously, even if targeted speciﬁc treatments would clarify the re-
levance of the altered pathways or functions in ASDs, on the other hand
the complex heterogeneity in ASDs children population could require a
multi-targeted approach. Here, we analysed the modulatory eﬀect of
PEA on many of the pathways and factors consistently associated to
ASDs pathology and symptoms.
Up to date, PEA has proven to be a multi-target compound: the main
pharmacological eﬀects of PEA are mediated by the activation of PPAR-
α (Lo Verme et al., 2005; LoVerme et al., 2006), a transcription factor
involved in the regulation of gene networks, which control pain and
inﬂammation (D'Agostino et al., 2009). This mechanism is supported by
the inhibition of neuronal ﬁring (Hansen, 2010) and by the stimulation
of neurosteroid synthesis, indicating that multiple mechanisms con-
tribute to the central eﬀect of PEA (Sasso et al., 2010). Indeed, PEA
levels seems to elevate in injured brain under pathophysiological sti-
muli, as shown in glutamate-treated neocortical neurons ex vivo
(Hansen et al., 1997) and in cortex after CNS injury (Berger et al., 2004;
Franklin et al., 2003), suggesting its key physiological role in main-
taining cellular homeostasis when faced with external stressors and
neuroinﬂammation. Consistently, tissue levels of PEA, as well as of
other N-acylethanolamines, were higher in the hippocampus of VPA-
exposed rats immediately following social exposure, indicating the in-
volvement of fatty acid amide alteration in behavioral abnormalities
observed in ASDs (Kerr, Downey, Conboy, Finn and Roche, 2013).
A recent study showed that PPAR-α activation prevents cognitive
deﬁcit (Greene-Schloesser et al., 2014) and increased hippocampal
neurogenesis after cerebral ischemia (Xuan et al., 2015). Indeed, this
receptor at hippocampal level modulates the expression of various
plasticity-related molecules and their functions via direct transcrip-
tional control of the master regulator CREB (Rivera et al., 2014; Roy
et al., 2013). Interestingly, an alteration of BDNF/TrkB signalling
pathway has been correlated with autism (Stephenson et al., 2011).
Consistently, a signiﬁcant reduction of BDNF-induced potentiation of
synaptic transmission was found in hippocampus from BTBR (Daimon
et al., 2015; Scattoni et al., 2013). Here, we found lower BDNF level
and no signiﬁcant changes of TrkB expression between BTBR and B6
mice; while repeated administrations of PEA increased both mRNA and
protein levels of BDNF and TrkB compared with BTBR mice. The in-
volvement of BDNF signalling pathway in the molecular mechanisms
contributing to PEA eﬀect, was conﬁrmed by the increase in the
phosphorylated state of CREB transcription factor, where several
pathways downstream TrkB activation were shown to converge, in
order to upregulate gene expression to exert pro-survival eﬀects and
synapse-enhancing function.
Apart from factors involved in synapse development and plasticity,
ASD pathogenesis also comprises other disparate alterations, including
mitochondrial dysfunction, dysregulated immune response and chronic
neuroinﬂammation. Mitochondria, the primary cellular energy-gen-
erating system, produce key factors during inﬂammation and oxidation
and constitute the main source of free radicals. Therefore, mitochon-
drial dysfunctions are related to inﬂammation and other energy-de-
pendent disturbances, where the generation of ROS exceeds the phy-
siological antioxidant activity, causing cellular oxidative damage
(Chan, 2017). Due to the higher mitochondrial energy demand of the
brain compared to other tissues, subtle changes in mitochondrial energy
production preferentially aﬀect the brain. Therefore, mitochondrial
dysfunction may be a key feature common to a wide spectrum of
neurological and neurodevelopmental diseases, including ASDs (Pei
and Wallace, 2018). For example, altered expression of electron
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transport chain genes have been observed in autism (Anitha et al.,
2013). Accordingly, hippocampal mitochondria in BTBR mice exhibited
a reduced respiratory capacity, as indicated by the decrease in succinate
State 3 oxygen consumption, which would partially block electron ﬂow
within the respiratory chain and consequently increase oxidative stress.
Further, the decreased SOD activity could contribute to excessive ROS
formation in BTBR mice. Notably, PEA treatment restored mitochon-
drial function and decreased oxidative stress partially due to the in-
crease in SOD activity. A concomitant decline in mitochondrial energy
eﬃciency, as evidenced by the decreased degree of coupling in PEA
treatment, may also contribute to counteract excessive ROS formation
in PEA-treated BTRB mice. In fact, one of the postulated roles of un-
coupling is known to be the maintenance of mitochondrial membrane
potential below the critical threshold for ROS production (Korshunov
et al., 1997). Together, these ﬁndings indicate that PEA counteracts
mitochondrial dysfunction and helps rescue brain energy metabolism
during pathological states, balancing ROS production/antioxidant de-
fences and limiting oxidative stress. Therefore, PEA could limit all those
events related to excessive ROS, such as the destruction of cellular
components including lipids, protein, and DNA, and ultimately cell
death via apoptosis or necrosis. Moreover, oxidative stress could trigger
redox-sensitive transcription factors and pro-inﬂammatory gene ex-
pression, sustaining the ongoing inﬂammatory state.
Many psychiatric disorders, as well as ASDs, are associated with
distinct inﬂammatory mechanisms in the periphery and in the CNS.
Neuroinﬂammation is driven by glial cells, in particular, activated mi-
croglial cells acquire a M1 phenotype, synthetizing pro-inﬂammatory
cytokines, such as TNF-α IL-1β, and IL-6. Indeed, all these cytokines
were found increased in the brain and blood from BTBR and VPA-
treated mice (Cipriani et al., 2018), a pro-inﬂammatory transcription
proﬁle related with the autistic traits in both mouse models. These al-
terations were also found in ASDs patients, where cytokines were ele-
vated both at CNS and serum level (Ahmad et al., 2018; Masi et al.,
2015; Vargas et al., 2005), strengthening the overall inﬂammation as a
typical feature shown in ASDs more than in other central disorders. It
has been underlined that the inﬂammatory state is also mediated by the
gastrointestinal system, due to increased permeability, synthesis of
cytokines and alteration of gut microbiota composition (Coretti et al.,
2017). Furthermore, BTBR mice show a number of immune abnorm-
alities, many of which are also observed in children with ASDs (Onore
et al., 2012). Here, in BTBR mice PEA was able to reduce cytokine
production, decreasing the inﬂammatory state at colonic, central and
systemic levels, and improved intestinal permeability. Therefore, it is
conceivable to hypothesise that systemic administration of PEA could
directly impact neuroinﬂammation, being able to cross the blood brain
barrier, but also indirectly reduce peripheral inﬂammatory input to the
brain, through its anti-inﬂammatory properties at colonic and systemic
level. Therefore, our hypothesis is that PEA would reduce the traf-
ﬁcking of inappropriate gut-derived detrimental factors into the portal
circulation and the crossing through a permissive blood–brain barrier,
leading to a reduction in systemic and ultimately central inﬂammation.
Actually, it was already proposed by de Theije et al. (2014) an in-
volvement of gut-brain axis in ASD by multiple ways, including cyto-
kines deriving from colonic inﬂammation, which could elicit and/or
sustain an immune response inﬂuencing at central level the altered
behaviour in ASDs.
Finally, PEA peripheral eﬀect could be also mediated by immune
alteration in the gastrointestinal tract, in turn possibly modulated by
gut microbiota changes. In fact, we observed a global alteration of
faecal microbial communities and, in particular, a variation in pro-
portion of Firmicutes and Bacteroidetes in BTBR mice upon PEA
treatment. A robust augment of Firmicutes, mainly due to the increase
of Unclassiﬁed genus of Clostridiales, to the expense of Bacteroidetes, is
the most evident alteration induced by PEA administration. Clostridia
include the majority of species able to produce butyrate as metabolic
product of anaerobic fermentation. Indeed, butyrate has a prominent
and beneﬁcial role in the maintenance of gut physiology in terms of
energy source for colonic epithelial cells, regulation of gut barrier
permeability, suppression of inﬂammation, modulation of immune
functions (Canani et al., 2011). Even though further analyses are
needed to identify deﬁnite bacterial species modulated by PEA treat-
ment, it is conceivable that its positive eﬀect on gut homeostasis may be
also associated to the remodelling of gut microbiota composition.
In conclusion, PEA showed to be a multifunctional compound,
worthy to be considered against complex diseases, such as autism and
its comorbidities, due to its pleiotropic mechanism of action, supporting
neuroprotection, anti-inﬂammatory eﬀects, and the modulation of gut-
brain axis, through restoring gut integrity and remodelling gut micro-
biota composition.
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